.jpg)
Could a hormone often feared by women actually reduce breast cancer risk? Join Dr. Hillary Lin, a Stanford-trained longevity physician with genetic risk herself, as she debunks myths, spotlights 2025 research, and reframes HRT from villain to potential health ally.
What You'll Learn:
• Insight into how estrogen and progesterone influence breast cancer—and why not all hormones are created equal
• A re-examination of the Women’s Health Initiative (WHI) findings, in context of age, timing, and hormone types
• Highlights from the E3N French study on natural (micronized) progesterone vs. synthetic progestins
• Absolute vs. relative risk explained—why HRT’s impact is often overstated
• The longevity case for HRT: bones, heart, brain, and healthspan benefits when started at “the window of opportunity”
• Real patient stories—including Dr. Lin’s own experience and how she counsels women with elevated cancer risk
• Critical caveats for breast cancer survivors and where non-hormonal alternatives come in
